carboplatin + cisplatin + gemcitabine + sintilimab

This is a combination regimen consisting of four agents: - **Carboplatin** and **cisplatin** are platinum-based chemotherapeutic agents that form DNA crosslinks, leading to apoptosis in rapidly dividing cells. - **Gemcitabine** is a nucleoside analog (antimetabolite) that inhibits DNA synthesis, also resulting in cell death. - **Sintilimab** is a monoclonal antibody targeting the programmed cell death protein 1 (PD-1), functioning as an immune checkpoint inhibitor to enhance anti-tumor immune responses. This combination would theoretically provide both cytotoxic chemotherapy and immunotherapy. While combinations of two or three of these drugs (e.g., gemcitabine plus cisplatin or carboplatin; platinum doublets with immunotherapy) are established for various cancers such as non-small cell lung cancer and urothelial carcinoma[2][3][4][5][6], there is no evidence from the provided sources for clinical use or trials specifically combining all four agents together. Sintilimab has been studied in combination with platinum-based chemotherapy (usually pemetrexed plus either cisplatin or carboplatin) for non-squamous NSCLC[7][9].

Brand names

TyvytGemzar

Other names

sintilimab + gemcitabine + platinum-based chemotherapysintilimab + GPsintilimab-GP